Anemia is one of the major contributing factors in maternal mortality and morbidity in third world countries. Adequate and early treatment of anemia in post-partum period will have improved quality of life in women of child bearing age group. Parenteral iron treatment is expected to be advantageous in patients with postpartum anemia. Objectives: To compare efficacy and safety of intravenous ferric carboxymaltose with iron sucrose in treatment of postpartum iron deficiency anemia in postpartum mothers at Maternity Hospital SKIMS, Soura. To reduce the prevalence of postpartum anemia. Methods: The present prospective study was conducted in the department of Obstetrics and Gynaecology at Maternity hospital SKIMS Soura, in the northern region of India from September 2017 to March 2019. Type of study: Prospective comparative observational study. Sample Size: A total of 200 patients with postpartum iron deficiency anemia were taken up in the study. They were randomly distributed into two groups consisting of 100 cases each. Group A: 100 cases in this group received intravenous ferric carboxymaltose therapy. Group B: 100 cases in this group received intravenous iron sucrose therapy. Results: Our study indicates that postpartum anemia can be treated effectively by ferric carboxymaltose as compared to iron sucrose because ferric carboxymaltose results in a much more rapid resolution of iron deficiency anemia due to its ability to deliver a high dose of iron within a short period of time. Conclusion: The study concluded that ferric carboxymaltose is safe intravenous agent for the treatment of iron deficiency anemia in postpartum period in comparison to Iron Sucrose.